Is ECTE a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

512 people get ECTE articles and Market Currents by email alert.

Get email alerts on ECTE »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Echo Therapeutics: A Gross Disregard To Shareholder Value
Jeffrey Fischer • Mon, Jun 17 • 9 Comments
Echo Therapeutics: Speculative Stock With Significant Upside Potential
David Zanoni • Mon, Dec 3, 2012 • 7 Comments
4 Reasons To Buy Echo Therapeutics
Markus Aarnio • Tue, May 29, 2012 • 8 Comments
Good News For Echo Therapeutics' Glucose Monitoring System
M. E. Garza • Thu, Oct 6, 2011
Echo Therapeutics: The Next 10-Bagger
David Zanoni • Tue, Aug 16, 2011 • 11 Comments
Echo Therapeutics: Positive Developments for a Needle-Free Diabetes Monitoring System
Mike Havrilla • Thu, Nov 19, 2009 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

Dario Seeks To Capitalize On New Technology For Diabetic Test Strips
Microcap Millionaires • Thu, May 16
LabStyle Innovations - Glucose Monitoring For The Mobile Age
Jason Napodano • Wed, May 15 • 13 Comments
5 Healthcare Companies With Insider Buying Filed On August 22 - 23
Markus Aarnio • Sat, Aug 25, 2012 • 2 Comments
6 Low Debt Pharmaceutical Stocks Rated Buy Or Better
ZetaKap • Mon, May 14, 2012 • 2 Comments
Cashing In On Diabetes: Novel Approaches
Jessica King Holden • Wed, Mar 7, 2012 • 3 Comments
Biotechnology FDA Approval Catalyst Strategy
David Pope - S&P Capital IQ • Fri, Jan 13, 2012 • 7 Comments
20 Micro-Cap Stocks Being Snapped Up By Hedge Funds
Kapitall • Thu, Dec 15, 2011
20 Healthcare Stocks Deeply Undervalued By Target Price
Kapitall • Wed, Nov 23, 2011 • 2 Comments
17 High-Growth Healthcare Stocks Being Bought Up By Hedge Funds
Kapitall • Sun, Nov 20, 2011 • 2 Comments
5 OTCBB Stocks That Began Trading on Major Exchanges in June
Alex Shadunsky • Tue, Jul 12, 2011 • 1 Comment
Diabetes Care: Global Investing Opportunities
Mike Havrilla • Sun, Nov 22, 2009 • 4 Comments

Echo Therapeutics's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012

Echo Therapeutics Announces Pricing of Public Offering of Common Stock

PR Newswire (Thu, 7:30PM)
Echo Therapeutics Submits Pre-Submission Package to FDA for Symphony® CGM System

PR Newswire (Jun 10, 2013)
Echo Therapeutics Announces Reverse Split of Common Stock

PR Newswire (Jun 6, 2013)
Echo Therapeutics Initiates CE Mark Clinical Trial of its Symphony® CGM System

PR Newswire (Jun 5, 2013)
Echo Therapeutics to Present at the Jefferies Global Healthcare Conference

PR Newswire (May 30, 2013)
Notified Body Accepts Echo Therapeutics' Clinical Trial Plan for Symphony® CGM System

PR Newswire (May 29, 2013)
Echo Therapeutics Announces Successful Unveiling of Symphony® CGM System

PR Newswire (May 23, 2013)
Echo Therapeutics Announces Institutional Review Board (IRB) Approval for Its Clinical Trial of the Symphony® CGM System

PR Newswire (May 21, 2013)
Echo Therapeutics to Unveil Symphony® CGM System in Webcast

PR Newswire (May 16, 2013)
Echo Therapeutics Announces First Quarter 2013 Financial Results

PR Newswire (May 10, 2013)
Echo Therapeutics, Inc. Announces 2012 Financial Results

PR Newswire (Mar 18, 2013)
Echo Therapeutics Achieves ISO 13485 Certification

PR Newswire (Mar 15, 2013)
Echo Therapeutics Appoints Robert Doman to Board of Directors

PR Newswire (Mar 13, 2013)
Echo Therapeutics Granted U.S. Patent for Prelude® SkinPrep System

PR Newswire (Mar 12, 2013)
Echo Therapeutics Announces Closing of Public Offering of Common Stock

PR Newswire (Feb 6, 2013)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Feb 1, 2013)
Echo Therapeutics Announces Pricing of Public Offering of Common Stock

PR Newswire (Jan 31, 2013)
Echo Therapeutics Announces Proposed Public Offering

PR Newswire (Jan 31, 2013)
Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony® tCGM System at the 42nd Critical Care Congress

PR Newswire (Jan 22, 2013)
Echo Therapeutics to Present at the Noble Financial Capital Markets' Ninth Annual Equity Conference

PR Newswire (Jan 15, 2013)

ECTE vs. ETF Alternatives

Company Description

Currently, there's no company description for ECTE.

Sector: Healthcare

Industry: Medical Appliances & Equipment

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, June 13, 11:54 PM Which is the chicken and which is the egg? Echo Therapeutics (ECTE -12.7%) dropped significantly on unusual volume to $2.89 during Thursday's market, then after the close released the pricing for a previously announced secondary public offering: 4M+ shares, at $2.70 a share. The offering is due to close June 19. Not surprisingly, ECTE is -3.8% AH. Comment! [Healthcare]
Thursday, June 13, 12:45 PM Midday top 10 gainers: BLC +27%. GCI +26%. CERE +19%. TVL +17%. LRAD +14%. GTN +13%. ENVI +13%. VSTM +12%. PXLW +12%. OVRL +11%.
Midday top 10 Losers: CHNG.PK -19%. HMTV -16%. EAC -15%. SGOC -14%. CREG -13%. CRTX -11%. RFIL -11%. VELT -10%. ECTE -10%. JVA -9%. 1 Comment [On the Move]
Wednesday, June 12, 12:45 PM Midday top 10 gainers: CERE +73%. CTB +41%. SGOC +28%. ULTA +17%. GPRC +14%. SE +10%. UQM +9%. AFFY +9%. AMED +9%. HMA +9%.
Midday top 10 Losers: IQNT -17%. KNDI -17%. CLSN -14%. TELK -12%. RLOG -12%. VRTB -11%. OSH -11%. CBAK -11%. ECTE -10%. CTC -10%. 1 Comment [On the Move]
Tuesday, June 11, 12:45 PM Midday top 10 gainers: SGOC +56%. BEAT +53%. UQM +30%. PGNX +26%. DOLE +21%. NOA +21%. QCOR +20%. VNDA +19%. ALTI +13%. CMGE +13%.
Midday top 10 Losers: GNMK -23%. LULU -17%. SMA -16%. ALVR -15%. LDK -10%. PRIS -10%. RSOL -10%. IMUC -9%. ECTE -9%. COCO -9%. 1 Comment [On the Move]
Monday, June 10, 12:45 PM Midday top 10 gainers: SGOC +25%. ACAD +17%. STEL +17%. MPAA +14%. TRMD +9%. OVAS +13%. CLIR +13%. TPLM +12%. RVLT +13%. KNDI +12%.
Midday top 10 Losers: DVAX -35%. OSH -18%. ECTE -16%. AFFY -14%. AEPI -14%. OMX -12%. SHI -12%. PLM -11%. GNRC -11%. CBAK -11%. 1 Comment [On the Move]
Monday, June 10, 10:27 AM Echo Therapeutics (ECTE -16%) trades lower this morning, coming off Friday's first day of trading following a 1-for-10 reverse split. Although there's no stand-alone driver for today's decline, the company did announce that it's submitted a pre-submission package to the FDA for using its Symphony CGM System in the hospital critical care environment. Additionally, the company has also requested a meeting with the agency to develop a clinical and regulatory plan to support the approval of the system. Comment! [Healthcare, On the Move]
Thursday, June 6, 4:59 PM Echo Therapeutics (ECTE) declares a 1-for-10 reverse split of issued and outstanding common stock, to be effective prior to the market opening tomorrow. The company's decision to split was made with intent to improve its capital structure and increase its per share market price, thereby allowing the company to maintain its Nasdaq listing. Comment! [Healthcare]
Wednesday, June 5, 8:38 AM Echo Therapeutics (ECTE) initiates a clinical trial of its Symphony CGM System (I, II), a move CEO Patrick Mooney calls "the final step before the submission of the CE Mark Technical File for potential market clearance and ensuing European commercial launch." (PR) Comment! [Healthcare]
Thursday, May 23, 3:46 PM Echo Therapeutics (ECTE +12.8%) move up on the Street's upbeat take on its Symphony CGM System, a needle-free continuous glucose monitoring system which the company unveiled and demonstrated in a webcast yesterday. CEO Patrick T. Mooney, M.D., commented that Symphony can effectively "improve glucose monitoring in hospitals and help alleviate the burden on both patients and caregivers," Patrick T. Mooney, M.D., chairman and CEO said in a statement released today. Comment! [Healthcare, On the Move]
Tuesday, May 21, 10:27 AM Echo Therapeutics (ECTE +2%) settles in following in 12% jump after the opening bell on the company's announcement that the clinical trial of its Symphony CGM System has received Institutional Review Board approval. The board approval enables the Symphony system, which is a non-invasive, wireless, transdermal continuous glucose monitoring platform, to offically start clinical evaluations for a European CE Mark. Comment! [Healthcare]
Friday, May 10, 7:55 AM Echo Therapeutics (ECTE): Q1 EPS of -$0.13 misses by $0.03. Revenue of $22.56M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 12, 11:03 AM Echo Therapeutics (ECTE +6.7%) says it's been granted a patent for its Prelude SkinPrep System, a device and method for preparing the skin to allow for analyte extraction or drug delivery. The system is a component of the company's Symphony GSM System, a non-invasive glucose monitoring system. Comment! [Healthcare, On the Move]
Friday, February 1, 4:02 PM Echo Therapeutics (ECTE -29.4%) gets slammed today, after it prices its previously announced 13.3M share offering at $0.75 apiece, a 35% discount to Thursday's closing price. 1 Comment [Healthcare, On the Move]
Friday, February 1, 12:45 PM Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move]
Friday, February 1, 9:10 AM Premarket gainers: ADNC +30%. TSYS +15%. RAD +9%. CTRP +8%. EDAP +7%. ALU +6%. DELL +6%. VVUS +5%. PRGO +5%.
Losers: ECTE -35%. OTT -23%. LTM -16%. SDR -11%. OCZ -8%. CLSN -7%. ALKS -7%. NMM -6%. TLAB -5%. Comment! [On the Move]
Thursday, January 31, 6:48 PM Echo Therapeutics (ECTE) announces a secondary offering, but no details of the size or terms were given. Aegis Capital is acting as the sole book-running manager for the offering. Shares -7.8% AH. Comment! [Healthcare, On the Move]

nohope
Feareth not! Sell in May hold trueth $NOK, $MTU, $MFG, $ONCS, $NBG, $ECTE, $IMRS and all
May 23, 1:51 AM
Reply (11)

• !Report Abuse
View all 11 replies
Leont68: And getting burned along the way lol
May 23, 9:50 AM
• !Report Abuse
Systembolaget: Scorched, yes. Burned, no. Diversification rules supreme still.
May 23, 10:24 AM
• !Report Abuse
Add a reply...

140 characters

pedromm
ECTE Rebounding
5/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ 6 Low Debt Pharmaceutical Stocks Rated Buy Or Better http://bit.ly/L0WSca $ASTX $ECTE $IPXL $KERX $RIGL $VTUS @ZetaKap #pharma
5/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ Just posted: 6 Low Debt Pharmaceutical Stocks Rated Buy Or Better http://bit.ly/L0WSca $ASTX $ECTE $IPXL $KERX $RIGL $VTUS @ZetaKap
5/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Illogical Investor
Echo Therapeutics ticker ECTE. Announces positive results from trial of non invasive glucose monitoring system and direct capital raise
12/6/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

David Zanoni
ECTE is trading in a channel approx. between $3 & $4 - it is now at the low end of the channel at $2.92
10/23/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nadia Kageff
Advice to ECTE - SOUNDS GOOD, HOPE TO BUY SHARES. IPO,WHEN? NKAGEFF1@HOTMAIL.COM
11/19/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

ECTE Echo Therapeutics

ECTE

Echo Therapeutics